Literature DB >> 27681539

Definition of Unfit for Standard Acute Myeloid Leukemia Therapy.

Heidi D Klepin1.   

Abstract

Determining who is fit or unfit for standard treatments among older adults with acute myeloid leukemia (AML) remains a challenge. However, available evidence can provide guidance on strategies to assess and categorize fitness. Evidence is strongest to guide identification of "frail" older adults at the time of diagnosis based on performance status, physical function, and comorbidity. Many older adults, with adequate performance status and comorbidity burden, however, may be better characterized as "vulnerable". These patients have subclinical impairments that limit resilience when stressed with intensive therapies. More sensitive assessment strategies are needed to differentiate fit and vulnerable older adults regardless of chronologic age. Research is ongoing to identify tools and approaches, such as geriatric assessment, that can enhance characterization of fitness for AML therapies. This review will highlight available evidence for assessment of fitness among older adults with AML and discuss implications for practice and research.

Entities:  

Keywords:  Acute myeloid leukemia; Elderly; Fitness; Geriatric assessment; Older

Mesh:

Substances:

Year:  2016        PMID: 27681539     DOI: 10.1007/s11899-016-0348-8

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN: 1558-8211            Impact factor:   3.952


  61 in total

1.  Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification.

Authors:  Meir Wetzler; Krzysztof Mrózek; Jessica Kohlschmidt; Hervé Dombret; Hartmut Döhner; Sylvain Pilorge; Utz Krug; Andrew J Carroll; Richard A Larson; Guido Marcucci; Wolfgang Hiddemann; Thomas Büchner; Clara D Bloomfield
Journal:  Haematologica       Date:  2013-10-04       Impact factor: 9.941

2.  Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study.

Authors:  Arti Hurria; Kayo Togawa; Supriya G Mohile; Cynthia Owusu; Heidi D Klepin; Cary P Gross; Stuart M Lichtman; Ajeet Gajra; Smita Bhatia; Vani Katheria; Shira Klapper; Kurt Hansen; Rupal Ramani; Mark Lachs; F Lennie Wong; William P Tew
Journal:  J Clin Oncol       Date:  2011-08-01       Impact factor: 44.544

3.  Most 70- to 79-year-old patients with acute myeloid leukemia do benefit from intensive treatment.

Authors:  Gunnar Juliusson
Journal:  Blood       Date:  2011-03-24       Impact factor: 22.113

4.  Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401.

Authors:  Arti Hurria; Constance T Cirrincione; Hyman B Muss; Alice B Kornblith; William Barry; Andrew S Artz; Linda Schmieder; Rafat Ansari; William P Tew; Douglas Weckstein; Jeffrey Kirshner; Kayo Togawa; Kurt Hansen; Vani Katheria; Richard Stone; Ilene Galinsky; John Postiglione; Harvey Jay Cohen
Journal:  J Clin Oncol       Date:  2011-02-28       Impact factor: 44.544

5.  On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group.

Authors:  B Löwenberg; R Zittoun; H Kerkhofs; U Jehn; J Abels; L Debusscher; C Cauchie; M Peetermans; G Solbu; S Suciu
Journal:  J Clin Oncol       Date:  1989-09       Impact factor: 44.544

6.  Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome.

Authors:  Christina A Meyers; Maher Albitar; Elihu Estey
Journal:  Cancer       Date:  2005-08-15       Impact factor: 6.860

7.  Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia.

Authors:  Hagop Kantarjian; Farhad Ravandi; Susan O'Brien; Jorge Cortes; Stefan Faderl; Guillermo Garcia-Manero; Elias Jabbour; William Wierda; Tapan Kadia; Sherry Pierce; Jianqin Shan; Michael Keating; Emil J Freireich
Journal:  Blood       Date:  2010-07-28       Impact factor: 22.113

8.  Polypharmacy in hospitalized older adult cancer patients: experience from a prospective, observational study of an oncology-acute care for elders unit.

Authors:  Kellie L Flood; Maria B Carroll; Cyndi V Le; Cynthia J Brown
Journal:  Am J Geriatr Pharmacother       Date:  2009-06

9.  Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML).

Authors:  Bernard Tawfik; Timothy S Pardee; Scott Isom; Sarunas Sliesoraitis; Allison Winter; Julia Lawrence; Bayard L Powell; Heidi D Klepin
Journal:  J Geriatr Oncol       Date:  2015-10-30       Impact factor: 3.599

10.  Quality of life beyond 6 months after diagnosis in older adults with acute myeloid leukemia.

Authors:  Shabbir M H Alibhai; Marc Leach; Vikas Gupta; George A Tomlinson; Joseph M Brandwein; Fernando Suarez Saiz; Mark D Minden
Journal:  Crit Rev Oncol Hematol       Date:  2008-09-07       Impact factor: 6.312

View more
  5 in total

Review 1.  Cytotoxic therapy in acute myeloid leukemia: not quite dead yet.

Authors:  Laura C Michaelis
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 2.  How and when to decide between epigenetic therapy and chemotherapy in patients with AML.

Authors:  Hervé Dombret; Raphael Itzykson
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 3.  The beginning of a new therapeutic era in acute myeloid leukemia.

Authors:  Christian Récher
Journal:  EJHaem       Date:  2021-07-27

Review 4.  Personalizing initial therapy in acute myeloid leukemia: incorporating novel agents into clinical practice.

Authors:  Christin B DeStefano; Christopher S Hourigan
Journal:  Ther Adv Hematol       Date:  2018-03-27

5.  Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia.

Authors:  Evan M Cherry; Diana Abbott; Maria Amaya; Christine McMahon; Marc Schwartz; Julie Rosser; Audrey Sato; Jeffrey Schowinsky; Anagha Inguva; Mohd Minhajuddin; Shanshan Pei; Brett Stevens; Amanda Winters; Craig T Jordan; Clayton Smith; Jonathan A Gutman; Daniel A Pollyea
Journal:  Blood Adv       Date:  2021-12-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.